logo

For the Inventor, By the Inventor

Paris, France

Institut Curie


USPTO Granted Patents = 161

% Expired Patents = 28.6



Trademarks = 4

Forward Citations = 533

Loading Chart...
Loading Chart...

326 inventors (with patents filed for the assignee):

goldMedal Jamal Tazi (39 out of 39 patents)

silverMedal Didier Scherrer (32 out of 35 patents)

bronzeMedal Romain Najman (31 out of 31 patents)

4.  Florence Mahuteau (23 out of 23 patents)

5.  Marie Dutreix (14 out of 14 patents)

6.  David Grierson (14 out of 18 patents)

7.  Jean-Louis Viovy (12 out of 24 patents)

8.  Pierre Roux (12 out of 17 patents)

9.  Aude Garcel (11 out of 11 patents)

10.  Jian-Sheng Sun (11 out of 11 patents)

11.  Sebastian Amigorena (9 out of 12 patents)

12.  Julien Santo (9 out of 9 patents)

13.  Florence Mahuteau-Betzer (9 out of 9 patents)

14.  Franck Perez (8 out of 10 patents)

15.  Ludger Johannes (8 out of 13 patents)


Core Competencies:
RNA Virus Treatment
Quinoline Derivatives
Cancer Biomarkers
Immune Cell Modifications
Therapeutic Compounds
Viral Infections
Synthetic Antibodies
Microfluidic Devices
In Vivo Delivery Systems
Dbait Molecules
Inflammatory Diseases
Cancer Treatment

161 patents:

1. 12673087 - MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTORS (2026-07-07),
2. 12662663 - USE OF A DEFICIENT FUSION PROTEIN FOR NUCLEASE ACTIVITY SO AS TO INDUCE MEIOTIC RECOMBINATIONS (2026-06-23),
3. 12640232 - CELL-FREE DETECTION OF METHYLATED PROSTATE TUMOUR (2026-05-26),
4. 12640231 - CELL-FREE DETECTION OF METHYLATED BREAST TUMOR (2026-05-26),
5. 12622926 - Immunotherapy targeting tumor neoantigenic peptides (2026-05-12),
6. 12618832 - Identification of cognate pairs of ligands and receptors (2026-05-05),
7. 12617756 - Substituted imidazolidines for treating a RNA virus infection (2026-05-05),
8. 12479802 - Phenyl-n-quinoline derivatives for treating a RNA virus infection (2025-11-25),
9. 12421206 - Aryl-n-aryl derivatives for treating a RNA virus infection (2025-09-23),
10. 12415781 - Compounds with biguanidyl radical and uses thereof (2025-09-16),
11. 12414991 - Azobenzene derivatives, process for their preparation and their use for therapeutic treatment associated with ionizing radiations (2025-09-16),
12. 12371741 - Method for detecting a mutation in a microsatellite sequence (2025-07-29),
13. 12371471 - Immune cells defective for SUV39H1 (2025-07-29),
14. 12308126 - Device and method for predicting a relapse of a cancer for a patient (2025-05-20),
15. 12300356 - Cell-free detection of methylated tumour DNA (2025-05-13),
Institut Curie, located in Paris, France, is a leading research institution dedicated to advancing cancer therapeutics. The organization specializes in innovative approaches to cancer treatment, focusing on areas such as RNA virus treatment, quinoline derivatives, and cancer biomarkers. Its research encompasses immune cell modifications and the development of therapeutic compounds aimed at combating viral infections. Additionally, Institut Curie explores cutting-edge technologies, including synthetic antibodies and microfluidic devices, to enhance cancer care and patient outcomes.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Institut Curie
161 Patents

#49 in

#177 in

#5,112 in the World

Paris, FR
Paris, France

Institut Curie

Forward Citations = 533

326 inventors:

goldMedal Jamal Tazi (39 out of 39 patents)

silverMedal Didier Scherrer (32 out of 35 patents)

bronzeMedal Romain Najman (31 out of 31 patents)

4.  Florence Mahuteau (23 out of 23 patents)

5.  Marie Dutreix (14 out of 14 patents)

Please report any incorrect information to [email protected]
Loading…